Pacific Biosciences of California, Inc. (PACB)

Over the past six months, Pacific Biosciences of California, Inc. (PACB) stock has experienced several events that have impacted its price. The stock price as of April 9, 2026, was $1.36 per share, representing a decline of 1.45% over the past year. Key events include the announcement of Q4 and full-year 2025 financial results, the sale of its short-read sequencing assets, partnerships and initiatives with iHope Initiative and DNAstack, the appointment of Chris Gibson to its Board of Directors, significant insider selling, and increased short interest.

The provided information does not explicitly detail demand seasonality for Pacific Biosciences of California, Inc.'s products and services. Fluctuations in academic funding have been noted to impact instrument revenue. Instrument shipments to hospital and clinic customers showed growth, suggesting a potential shift or diversification in demand drivers. The company reported strong Revio and Vega shipments and record consumables revenue in Q4 2025, indicating momentum towards the end of the year. External factors like funding cycles and product adoption rates can influence demand in different quarters.

Pacific Biosciences of California, Inc. (PacBio) is a biotechnology company specializing in advanced sequencing solutions for genetic analysis. Founded in 2004 and headquartered in Menlo Park, California, PacBio's core business revolves around its SMRT sequencing technology, enabling high-accuracy, long-read sequencing. The company's major products include instruments like the Sequel, Sequel IIe, Revio and Vega systems, along with consumables and data analysis software, utilized across a broad range of life science research applications. PacBio also offers an emerging SBB short-read sequencing technology, with products provided for research use only.

Pacific Biosciences of California, Inc. has a global presence, serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe, and Asia. The majority of PacBio's revenue is derived from the Americas, followed by Europe, the Middle East, and Africa, and then Asia-Pacific. The company maintains a network of distribution and service partners to support instrument installation, training, and technical support in key markets worldwide.

In the past year, Pacific Biosciences of California has engaged in several activities that could positively influence its brand reputation within the scientific and investment communities. These include strategic partnerships and advancements in its technology. The company has announced collaborations such as with DNAstack and with Basecamp Research. PacBio continues to emphasize its HiFi long-read sequencing technology. The appointment of Chris Gibson to the Board of Directors could be seen as a move to strengthen leadership and expertise. The decline in stock price and increased short interest could indirectly reflect investor sentiment and potentially influence perception.

Pacific Biosciences of California, Inc. has a diverse ownership structure. Institutional investors hold a substantial portion of the company, with 57.4% to 66.47% of shares. The general public holds approximately 35% of the company's shares. Insiders own under 1% to 8.04% of the company. Major institutional owners include ARK Investment Management LLC, BlackRock, Inc., Softbank Group Corp, Vanguard Group Inc, Sumitomo Mitsui Trust Holdings, Inc. / Sumitomo Mitsui Trust Group Inc, Geode Capital Management, Llc, State Street Corp, D. E. Shaw & Co., Inc., Millennium Management Llc, and Amova Asset Management Americas Inc. Brook H. Byers is reported as the largest individual shareholder.